Topline CORE and CORE2 data show 85% pancreatitis reduction with olezarsen

Topline olezarsen data from the Phase 3 CORE and CORE2 trials in patients with severe hypertriglyceridaemia (sHTG) show significant placebo-adjusted mean reductions in fasting TG of up to 72% at six months (see table below).